

WEST Search History

DATE: Friday, January 07, 2005

Hide?	<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>
		<i>DB=USPT; PLUR=YES; OP=AND</i>	
<input type="checkbox"/>	L1	Haynes.in. or arrington.in.	1323
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=AND</i>	
<input type="checkbox"/>	L2	Haynes.in. or arrington.in.	3200
<input type="checkbox"/>	L3	transdermal\$ or trans-dermal\$ or transcutaneous\$ or trans-cutaneous\$ or transmucosal\$ or trans-mucosal\$	53708
<input type="checkbox"/>	L4	L3 and (l1 or l2)	19

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 19 of 19 returned.**

-
- ☐ 1. [20040202675](#). 09 Dec 03. 14 Oct 04. Vaccine adjuvant. [Haynes](#), Barton F.. 424/185.1; 514/44 A61K048/00 A61K039/00.
-
- ☐ 2. [20030206909](#). 07 Feb 03. 06 Nov 03. Human monoclonal antibodies against membrane proteins. Hua, Shaobing, et al. 424/160.1; 435/339.1 514/220 514/263.31 530/388.35 A61K039/42 A61K031/522 C12N005/06 C07K016/10.
-
- ☐ 3. [20030162733](#). 26 Nov 01. 28 Aug 03. Nucleic acid adjuvants. [Haynes](#), Joel R., et al. 514/44; 435/375 A61K048/00 C12N005/00.
-
- ☐ 4. [20030124718](#). 20 May 02. 03 Jul 03. Vaccine composition. Fuller, Deborah, et al. 435/320.1; 424/199.1 424/225.1 435/226 435/372 435/6 435/69.1 536/23.2 C12Q001/68 C07H021/04 C12N009/64 C12P021/02 C12P021/06 A61K039/12 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74 C12N005/08 A61K039/29.
-
- ☐ 5. [20020165176](#). 30 Apr 01. 07 Nov 02. Nucleic acid immunization. [Haynes](#), Joel R., et al. 514/44; A61K048/00.
-
- ☐ 6. [6584349](#). 17 Nov 97; 24 Jun 03. Low cost electrodes for an iontophoretic device. Sage, Jr.; Burton H., et al. 604/20; A61N001/30.
-
- ☐ 7. [6193731](#). 27 Oct 98; 27 Feb 01. Laparoscopic insertion and deployment device. Oppelt; William G., et al. 606/151; 604/13. A61B017/08.
-
- ☐ 8. [5556871](#). 24 Apr 95; 17 Sep 96. Method for treating epithelial precancerous lesions with topical inidazoles. Halperin; Jose, et al. 514/396; 514/254.07 514/399. A61K031/415.
-
- ☐ 9. [5310403](#). 18 May 92; 10 May 94. Iontophoretic drug delivery device and circuit therefor. [Haynes](#); John L.. 604/20; 607/154. A61N001/30.
-
- ☐ 10. [5306235](#). 30 Sep 92; 26 Apr 94. Failsafe iontophoresis drug delivery system. [Haynes](#); John L.. 604/20; 607/149. A61N001/30.
-
- ☐ 11. [5246418](#). 17 Dec 91; 21 Sep 93. Iontophoresis system having features for reducing skin irritation. [Haynes](#); John L., et al. 604/20; 607/152. A61N001/30.
-
- ☐ 12. [5131403](#). 05 Jun 91; 21 Jul 92. Method for obtaining blood using iontophoresis. [Haynes](#); John L.. 600/573; 604/20. A61B005/00.
-
- ☐ 13. [WO009711744A1](#). 27 Sep 96. 03 Apr 97. LOW-COST ELECTRODES FOR AN IONTOPHORETIC DEVICE. REDDY, VILAMBI NRK, et al. A61N001/30;.
-
- ☐ 14. [EP000535530A1](#). 24 Sep 92. 07 Apr 93. Extended-life drug filled patch.. HAYNES, JOHN L. 604/890.1. A61K033/24; A61L015/44 A61M035/00 A61N001/18.
-
- ☐ 15. [WO 9711744A](#). Low-cost electrode system for iontophoretic drug delivery device - has anode

electrode comprising bulk base metal coated with dissimilar precious or chemically inert metal preventing chemical reaction between base metal and electrolyte. BOCK, C R, et al. A61N001/30.

☐ 16. WO 9407566A. Iontophoric drug delivery system safety circuit - which either interrupts or maintains current to iontophoretic electrodes if any circuit components or power source fail.. HAYNES, J L. A61N001/30 A61N001/32.

☐ 17. WO 9323114A. Iontophoretic drug delivery system with segmented electrode - has arrangement for ensuring that each electrode segment passes the same current. HAYNES, J L. A61N001/30.

☐ 18. EP 535530A. Drug-filled transdermal patches contg. preservative - comprising antimicrobial metal, having long shelf-life without need for irradiation etc.. HAYNES, J L. A61J001/14 A61K009/70 A61K031/28 A61K033/24 A61L015/44 A61M035/00 A61N001/18.

☐ 19. EP 517120B. Ionophoretic delivery of bactericide through a patient's skin - preceding the taking of blood from the patient at the delivery site. HAYNES, J L. A61B005/00 A61B005/14 A61N001/30.

Generate Collection

Print

Terms	Documents
L3 and (L1 or L2)	19

[Prev Page](#) [Next Page](#) [Go to Doc#](#)

Pertussis toxin is a multi-subunit protein comprised of an A protomer consisting of a single catalytic S1 subunit, and a B oligomer containing one S2, one S3, two S4, and one S5 subunits. The B oligomer binds the toxin to specific receptors on target cells, thus delivering the S1 subunit to the cell membrane where, after it is activated, it catalyzes the transfer of ADP-ribose from NAD to a specific cysteine residue in specific acceptor proteins, typically the alpha subunit of regulatory proteins, termed G-proteins, that bind guanine nucleotides [Ui, M. (1990) in ADP-Ribosylating Toxins and G Proteins (Moss, J., & Vaughan, M., Eds.) Chapter 4, pp. 45-77, American Society Society for Microbiology, Washington, D.C.]